HROB

Summary

HROB (homologous recombination factor with OB-fold, HGNC:28460) is a protein-coding gene on chromosome 17q21.31, encoding Homologous recombination OB-fold protein (Q8N3J3). DNA-binding protein involved in homologous recombination that acts by recruiting the MCM8-MCM9 helicase complex to sites of DNA damage to promote DNA repair synthesis.

Predicted to enable single-stranded DNA binding activity. Involved in DNA synthesis involved in DNA repair and interstrand cross-link repair. Located in site of DNA damage.

Source: NCBI Gene 78995 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 20 total — 2 pathogenic
• Phenotypes (HPO): 11
• MANE Select transcript: NM_001171251

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28460
Approved symbol	HROB
Name	homologous recombination factor with OB-fold
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Aliases	MGC3130, MCM8IP
Ensembl gene	ENSG00000125319
Ensembl biotype	protein_coding
OMIM	618611
Entrez	78995

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 28 protein_coding, 2 retained_intron

ENST00000245382, ENST00000319977, ENST00000585683, ENST00000588073, ENST00000588434, ENST00000910121, ENST00000910122, ENST00000910123, ENST00000910124, ENST00000934733, ENST00000934734, ENST00000934735, ENST00000934736, ENST00000934737, ENST00000934738, ENST00000934739, ENST00000934740, ENST00000934741, ENST00000934742, ENST00000934743, ENST00000934744, ENST00000934745, ENST00000934746, ENST00000934747, ENST00000934748, ENST00000934749, ENST00000934750, ENST00000934751, ENST00000934752, ENST00000934753

RefSeq mRNA: 4 — MANE Select: NM_001171251 NM_001171251, NM_001321310, NM_001321311, NM_024032

CCDS: CCDS11477, CCDS59293, CCDS82136

Canonical transcript exons

ENST00000585683 — 10 exons

Exon	Start	End
ENSE00001118649	44145203	44145253
ENSE00001260412	44154556	44154664
ENSE00001260423	44152637	44152777
ENSE00001260435	44150961	44151044
ENSE00001390690	44147858	44149027
ENSE00002843161	44141930	44142145
ENSE00003509780	44155286	44155411
ENSE00003607078	44154853	44154938
ENSE00003656631	44157833	44157941
ENSE00003692068	44161871	44162476

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 88.93.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.2791 / max 167.4429, expressed in 1400 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161111	3.3875	1108
161114	1.6287	750
161112	1.3207	600
161113	0.9422	460

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.93	gold quality
type B pancreatic cell	CL:0000169	87.32	gold quality
diaphragm	UBERON:0001103	86.55	gold quality
olfactory bulb	UBERON:0002264	86.05	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.45	gold quality
oocyte	CL:0000023	81.25	gold quality
right testis	UBERON:0004534	80.21	gold quality
left testis	UBERON:0004533	79.92	gold quality
left ventricle myocardium	UBERON:0006566	79.29	gold quality
testis	UBERON:0000473	78.85	gold quality
myocardium	UBERON:0002349	78.69	gold quality
heart right ventricle	UBERON:0002080	77.51	gold quality
cardiac muscle of right atrium	UBERON:0003379	77.27	gold quality
ventricular zone	UBERON:0003053	76.83	gold quality
vastus lateralis	UBERON:0001379	76.38	gold quality
secondary oocyte	CL:0000655	76.26	gold quality
nasal cavity epithelium	UBERON:0005384	76.24	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	76.04	gold quality
quadriceps femoris	UBERON:0001377	75.63	gold quality
buccal mucosa cell	CL:0002336	75.50	gold quality
ganglionic eminence	UBERON:0004023	75.09	gold quality
stromal cell of endometrium	CL:0002255	74.46	gold quality
bone marrow	UBERON:0002371	73.98	gold quality
hair follicle	UBERON:0002073	73.83	gold quality
gluteal muscle	UBERON:0002000	73.41	gold quality
mucosa of urinary bladder	UBERON:0001259	72.94	gold quality
triceps brachii	UBERON:0001509	72.75	gold quality
biceps brachii	UBERON:0001507	72.65	gold quality
male germ cell	CL:0000015	72.39	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	72.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.49

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

21 targeting HROB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-7515	99.31	68.22	1795
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-4764-5P	98.88	65.53	894
HSA-MIR-9903	98.47	66.70	748
HSA-MIR-4722-5P	98.46	66.34	1611
HSA-MIR-6864-5P	98.38	66.59	1079
HSA-MIR-624-3P	98.37	67.06	1067
HSA-MIR-6842-3P	98.07	66.33	1325
HSA-MIR-7113-5P	97.88	67.33	1735
HSA-MIR-6847-3P	96.50	67.30	582
HSA-MIR-635	96.00	65.54	687
HSA-MIR-6774-5P	95.94	65.18	722
HSA-MIR-3193	92.99	64.93	116

Literature-anchored findings (GeneRIF, showing 6)

• The C17orf53 SNP rs227584 is associated with human bone density and bone fractures risk. (PMID:30370607)
• C17orf53/HROB is an OB-fold-containing factor involved in HR that acts by recruiting the MCM8-MCM9 helicase to sites of DNA damage to promote DNA synthesis (PMID:31467087)
• MCM8IP activates the MCM8-9 helicase to promote DNA synthesis and homologous recombination upon DNA damage. (PMID:32528060)
• C17orf53 is identified as a novel gene involved in inter-strand crosslink repair. (PMID:32853826)
• Meiotic genes in premature ovarian insufficiency: variants in HROB and REC8 as likely genetic causes. (PMID:34707299)
• Mechanism of DNA unwinding by MCM8-9 in complex with HROB. (PMID:38678026)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	hrob	ENSDARG00000096229
mus_musculus	Hrob	ENSMUSG00000034773
rattus_norvegicus	Hrob	ENSRNOG00000020908

Protein

Protein identifiers

Homologous recombination OB-fold protein — Q8N3J3 (reviewed: Q8N3J3)

All UniProt accessions (1): Q8N3J3

UniProt curated annotations — full annotation on UniProt →

Function. DNA-binding protein involved in homologous recombination that acts by recruiting the MCM8-MCM9 helicase complex to sites of DNA damage to promote DNA repair synthesis. A C-terminal region including the OB-fold stimulates the helicase activity of MCM8-MCM9 probably by altering its conformation.

Subunit / interactions. Interacts with MCM8; this interaction is necessary for MCM8-MCM9 helicase complex recruitment to DNA damage sites. Interacts with the MCM8-MCM9 complex.Interacts with RPA1; this interaction associates HROB with the RPA complex.

Subcellular location. Nucleus. Chromosome.

Disease relevance. Ovarian dysgenesis 11 (ODG11) [MIM:620897] An autosomal recessive form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8N3J3-1	1	yes
Q8N3J3-2	2
Q8N3J3-3	3
Q8N3J3-4	4

RefSeq proteins (4): NP_001164722, NP_001308239, NP_001308240, NP_076937 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028045	HROB	Family
IPR058570	HROB_OB	Domain

Pfam: PF15072

UniProt features (23 total): splice variant 6, modified residue 5, region of interest 4, compositionally biased region 4, sequence variant 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N3J3-F1	55.18	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 285, 295, 329, 337, 47

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 147 (showing top): GOBP_MALE_GAMETE_GENERATION, IWANAGA_E2F1_TARGETS_INDUCED_BY_SERUM, GOBP_DNA_DAMAGE_RESPONSE, GOBP_DNA_BIOSYNTHETIC_PROCESS, GOBP_INTERSTRAND_CROSS_LINK_REPAIR, GOBP_DNA_SYNTHESIS_INVOLVED_IN_DNA_REPAIR, GOBP_FEMALE_GAMETE_GENERATION, FISCHER_DREAM_TARGETS, GOBP_RECOMBINATIONAL_REPAIR, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, GOMF_SINGLE_STRANDED_DNA_BINDING, NUYTTEN_EZH2_TARGETS_DN, MARSON_BOUND_BY_E2F4_UNSTIMULATED, GCCNNNWTAAR_UNKNOWN, GOBP_DNA_METABOLIC_PROCESS

GO Biological Process (9): recombinational repair (GO:0000725), DNA synthesis involved in DNA repair (GO:0000731), DNA damage response (GO:0006974), female gamete generation (GO:0007292), interstrand cross-link repair (GO:0036297), male gamete generation (GO:0048232), DNA repair (GO:0006281), DNA recombination (GO:0006310), DNA biosynthetic process (GO:0071897)

GO Molecular Function (3): single-stranded DNA binding (GO:0003697), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), site of DNA damage (GO:0090734), chromosome (GO:0005694)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA repair	3
DNA metabolic process	3
gamete generation	2
DNA recombination	1
DNA biosynthetic process	1
cellular response to stress	1
DNA damage response	1
nucleic acid biosynthetic process	1
DNA binding	1
nucleic acid binding	1
binding	1
intracellular membrane-bounded organelle	1
chromosome	1
cellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

440 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HROB	A0A494C100	A0A494C100	658
HROB	MCM8	Q9UJA3	658
HROB	ZBTB40	Q9NUA8	530
HROB	TMEM89	A2RUT3	507
HROB	MCM9	Q9NXL9	476
HROB	STARD3NL	O95772	447
HROB	FAM199X	Q6PEV8	447
HROB	MIMS1	Q96ND0	445
HROB	DCDC1	P59894	433
HROB	GARIN5A	Q6IPT2	431
HROB	CCDC170	Q8IYT3	430
HROB	J3KS56	J3KS56	405
HROB	AKAP11	Q9UKA4	399
HROB	EFCC1	Q9HA90	380
HROB	ZNF738	Q8NE65	373

IntAct

9 interactions, top by confidence:

A	B	Type	Score
MSH6	PCNA	psi-mi:“MI:0914”(association)	0.530
PIK3R3	HROB	psi-mi:“MI:0915”(physical association)	0.370
HROB	PRMT1	psi-mi:“MI:0915”(physical association)	0.370
LRRK2	TK1	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
ZNRD2	KRBA1	psi-mi:“MI:0914”(association)	0.350
PRPS2	SMCHD1	psi-mi:“MI:0914”(association)	0.350
HROB	ZPR1	psi-mi:“MI:0914”(association)	0.350

BioGRID (56): C17orf53 (Two-hybrid), C17orf53 (Affinity Capture-MS), C17orf53 (Affinity Capture-MS), C17orf53 (Affinity Capture-MS), C17orf53 (Affinity Capture-MS), MARS2 (Affinity Capture-MS), ZPR1 (Affinity Capture-MS), C17orf53 (Two-hybrid), C17orf53 (Affinity Capture-MS), C17orf53 (Proximity Label-MS), C17orf53 (Two-hybrid), C17orf53 (Proximity Label-MS), C17orf53 (Proximity Label-MS), C17orf53 (Two-hybrid), C17orf53 (Two-hybrid)

ESM2 similar proteins: A0P8Z5, A2ACJ2, D3YYM4, G3HKI1, G5E8P0, O15040, P97432, Q0VG06, Q13426, Q14159, Q14596, Q1JQA1, Q32P12, Q3KNJ2, Q3T1H6, Q3TAA7, Q3ZBK8, Q3ZK22, Q4AC94, Q501R9, Q52KB6, Q5E9K8, Q5FVL7, Q5FVM3, Q5RA50, Q5RC94, Q5XI52, Q60953, Q6GX86, Q6NV18, Q6P2K3, Q7L4P6, Q810L3, Q86V42, Q8BGX7, Q8BX13, Q8C2A2, Q8C6D4, Q8K015, Q8N3J3

Diamond homologs: Q32P12, Q6GX86, Q8N3J3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

20 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	4
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
3255476	NM_001171251.3(HROB):c.718C>T (p.Arg240Ter)	Pathogenic
3255477	NM_001171251.3(HROB):c.1351C>T (p.Arg451Ter)	Pathogenic

SpliceAI

1910 predictions. Top by Δscore:

Variant	Effect	Δscore
17:44142142:TATGG:T	donor_loss	1.0000
17:44142143:ATGG:A	donor_loss	1.0000
17:44142144:TGGT:T	donor_loss	1.0000
17:44142145:GGTA:G	donor_loss	1.0000
17:44142146:G:GC	donor_loss	1.0000
17:44142147:T:A	donor_loss	1.0000
17:44150960:GCAGA:G	acceptor_gain	1.0000
17:44154550:A:AG	acceptor_gain	1.0000
17:44154551:A:G	acceptor_gain	1.0000
17:44154663:GG:G	donor_gain	1.0000
17:44154664:GG:G	donor_gain	1.0000
17:44154847:TTGCA:T	acceptor_loss	1.0000
17:44154848:TGCA:T	acceptor_loss	1.0000
17:44154849:GCAG:G	acceptor_loss	1.0000
17:44154851:A:G	acceptor_loss	1.0000
17:44154852:G:T	acceptor_loss	1.0000
17:44154852:GGA:G	acceptor_gain	1.0000
17:44154936:CAGGT:C	donor_loss	1.0000
17:44154937:AGGT:A	donor_loss	1.0000
17:44154938:GGT:G	donor_loss	1.0000
17:44154939:G:T	donor_loss	1.0000
17:44154940:T:A	donor_loss	1.0000
17:44155277:T:TA	acceptor_gain	1.0000
17:44155283:CAGA:C	acceptor_loss	1.0000
17:44155284:A:AG	acceptor_gain	1.0000
17:44155284:AGATT:A	acceptor_gain	1.0000
17:44155285:G:GA	acceptor_gain	1.0000
17:44155285:GA:G	acceptor_gain	1.0000
17:44155285:GAT:G	acceptor_gain	1.0000
17:44155285:GATT:G	acceptor_gain	1.0000

AlphaMissense

4175 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:44154650:T:C	F516S	0.997
17:44154864:G:A	G525R	0.995
17:44154864:G:C	G525R	0.995
17:44152688:T:A	W454R	0.994
17:44152688:T:C	W454R	0.994
17:44154864:G:T	G525W	0.994
17:44155323:T:A	L562H	0.994
17:44154865:G:A	G525E	0.993
17:44154925:T:C	L545P	0.993
17:44154931:T:C	L547P	0.993
17:44155323:T:C	L562P	0.993
17:44155329:T:A	V564E	0.993
17:44152754:A:C	S476R	0.992
17:44152756:C:A	S476R	0.992
17:44152756:C:G	S476R	0.992
17:44154922:T:A	V544E	0.991
17:44155295:T:C	F553L	0.991
17:44155297:T:A	F553L	0.991
17:44155297:T:G	F553L	0.991
17:44148995:T:C	F398L	0.990
17:44148996:T:C	F398S	0.990
17:44148997:C:A	F398L	0.990
17:44148997:C:G	F398L	0.990
17:44154587:T:A	V495D	0.990
17:44154602:T:A	V500E	0.990
17:44155327:C:A	N563K	0.990
17:44155327:C:G	N563K	0.990
17:44154599:C:A	A499E	0.989
17:44155344:T:C	L569P	0.989
17:44152690:G:C	W454C	0.988

dbSNP variants (sampled 300 via entrez): RS1000279950 (17:44156356 C>G), RS1000500311 (17:44143191 G>T), RS1000529349 (17:44143457 C>T), RS1000580707 (17:44162603 C>T), RS1000594691 (17:44156606 C>G,T), RS1000669610 (17:44156599 G>A), RS1000705193 (17:44149866 G>A,T), RS1000789910 (17:44150097 C>T), RS1001171753 (17:44146119 G>A), RS1001181303 (17:44150317 G>A), RS1001204494 (17:44146558 C>G), RS1001326139 (17:44140002 T>A,C), RS1001614062 (17:44146225 T>G), RS1001624004 (17:44145846 G>C), RS1001842803 (17:44153217 T>A,C)

Disease associations

OMIM: gene MIM:618611 | disease phenotypes: MIM:620897

GenCC curated gene-disease

Mondo (2): premature menopause (MONDO:0001119), ovarian dysgenesis 11 (MONDO:0971176)

Orphanet (0):

HPO phenotypes

11 total (11 of 11 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000786	Primary amenorrhea
HP:0000823	Delayed puberty
HP:0003621	Juvenile onset
HP:0008214	Decreased serum estradiol
HP:0008232	Elevated circulating follicle stimulating hormone level
HP:0010463	Aplasia of the ovary
HP:0011969	Elevated circulating luteinizing hormone level
HP:0012569	Delayed menarche
HP:0025708	Early young adult onset
HP:0031103	Decreased circulating antimullerian hormone circulation

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000297_4	Bone mineral density (hip)	9.000000e-07
GCST007691_34	Femoral neck bone mineral density	3.000000e-24
GCST008103_24	Bipolar disorder	2.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007785	femoral neck bone mineral density

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008594	Menopause, Premature	C12.050.351.500.056.630.250; C12.100.250.056.630.250; G08.686.157.500.500; G08.686.841.249.500.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression	3
sodium arsenite	decreases expression, increases abundance, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Arsenic	increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
aristolochic acid I	increases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
sodium arsenate	increases abundance, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
potassium chromate(VI)	increases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	decreases expression	1
Calcitriol	decreases expression, affects cotreatment	1
Cannabidiol	increases expression	1
Cisplatin	increases expression, affects cotreatment	1
Doxorubicin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Smoke	decreases expression	1
Testosterone	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
1-Methyl-4-phenylpyridinium	decreases expression	1
Aflatoxin B1	increases expression	1
Okadaic Acid	increases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

82 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists